EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Basculer en Français

8304	Companies
115195	Keywords
55510	Articles
62563	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

BRIEF

published on 04/24/2024 at 12:20, 6 months 27 days ago

Significant Clinical Improvements Reported in enVVeno Medical's VenoValve Pivotal Trial

FDA Approval Clinical Trial VenoValve Charing Cross Symposium Venous Disease
PRESS RELEASE

published on 04/24/2024 at 12:15, 6 months 27 days ago

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
enVVeno Medical presents positive efficacy data on VenoValve from SAVVE U.S. pivotal trial at Charing Cross International Symposium, showing clinical improvement for severe CVI patients

FDA Approval VenoValve SAVVE Trial CVI Patients Venous Disease
BRIEF

published on 04/16/2024 at 15:05, 7 months 5 days ago

EnVVeno Medical présentera de nouvelles données sur l'efficacité de VenoValve au symposium de Charing Cross

Essais Cliniques EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Symposium De Charing Cross
BRIEF

published on 04/16/2024 at 15:05, 7 months 5 days ago

EnVVeno Medical to Present New VenoValve Efficacy Data at Charing Cross Symposium

Clinical Trials EnVVeno Medical VenoValve Chronic Venous Insufficiency Charing Cross Symposium
PRESS RELEASE

published on 04/16/2024 at 15:00, 7 months 5 days ago

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation

VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRIEF

published on 04/09/2024 at 14:50, 7 months 12 days ago

EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve®

EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
BRIEF

published on 04/09/2024 at 14:50, 7 months 12 days ago

EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
PRESS RELEASE

published on 04/09/2024 at 14:45, 7 months 12 days ago

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024

FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
BRIEF

published on 03/15/2024 at 14:05, 8 months 6 days ago

EnVVeno Medical to Showcase Its Innovations in an Upcoming Virtual Investor Event

EnVVeno Medical Medical Innovation Virtual Investor Event Venous Disease Treatment Corporate Overview
BRIEF

published on 03/15/2024 at 14:05, 8 months 6 days ago

EnVVeno Medical présentera ses innovations lors d'un prochain événement virtuel pour les investisseurs

Innovation Médicale EnVVeno Medical Événement Virtuel Pour Les Investisseurs Traitement Des Maladies Veineuses Vue D'ensemble De L'entreprise

Accesswire

Published on 11/22/2024 at 09:00, 1 hour 48 minutes ago

Industrial Software Company mlean Celebrates 10 Years of Continuous Improvement
Published on 11/22/2024 at 00:00, 10 hours 48 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 12 hours 43 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 12 hours 58 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 14 hours 33 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals

View all ACCESSWIRE

EQS Group

Published on 11/22/2024 at 09:45, 1 hour 3 minutes ago

The GSMA – China Unicom Open Gateway Global Use Case Innovation Challenge has begun!
Published on 11/22/2024 at 09:23, 1 hour 25 minutes ago

Turkiye Garanti Bankasi A.S.: Announcement regarding issuance of subordinated notes
Published on 11/22/2024 at 09:06, 1 hour 41 minutes ago

Original-Research: NFON AG (von NuWays AG): Buy
Published on 11/22/2024 at 09:05, 1 hour 42 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 11/22/2024 at 09:03, 1 hour 44 minutes ago

Amundi Physical Metals plc: UK Final Terms

Les Echos

Published on 11/21/2024 at 06:58, 1 day 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 3 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 14 hours ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 15 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE